Controversies of Diagnosing Autoimmune Retinopathy

Heckenlively,; Ha, Ferreyra; Jayasundera, Thiran

doi:10.1001/archophthalmol.2009.372

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although AIR have been studied for the past 40 years [1, 2], they remain difficult to diagnose [3] and treat. AIR include such conditions as paraneoplastic autoimmune retinopathy (pAIR), which can be further subdivided into cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Boudreault

Justus

Sengillo

et al. 2017

Orphanet J Rare Dis

View full text Add to dashboard Cite

BackgroundAutoimmune retinopathy (AIR) is a rare but potentially blinding condition that is often underdiagnosed. Common features in AIR presentation include rapidly progressive vision loss with abnormal electrophysiological responses of the retina associated with positive anti-retinal antibodies. AIR is also challenging to treat, and thus, the introduction of new potential therapeutic agents is welcomed. The goal of this communication is to assess the effects of rituximab infusions on electroretinogram (ERG) responses and visual function outcomes in patients with non-paraneoplastic autoimmune retinopathy (npAIR).ResultsFollowing infusion(s), three out of five patients showed no evidence of disease progression or improved, while two patients continued to progress on ERG. One patient demonstrated improvement in visual acuity (2 lines) in both eyes. ERG responses provided objective monitoring of patients’ visual function and response to immunosuppression over time.ConclusionsThese findings suggest that patients with npAIR unresponsive to other immunosuppression therapies may benefit from rituximab infusion, although stabilization rather than improvement was more frequently the outcome in our case series. Furthermore, regularly scheduled ERG follow-up examinations are recommended for monitoring patients’ progression during treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Boudreault

Justus

Sengillo

et al. 2017

Orphanet J Rare Dis

View full text Add to dashboard Cite

show abstract

“…However, there has been one retrospective review of diabetic patients receiving rosiglitazone which revealed a reduction in development of proliferative DR [4], although this paper was criticised because of unmatched controls [36]. TZDs have also been trialled in animal models and were found to reduce choroidal neovascularisation [37]. Interestingly, the TZDs in this study were given by intraocular injection, suggesting that this delivery route of PPAR agonists might also be efficacious in humans [37].…”

Section: Introductionmentioning

confidence: 99%

“…TZDs have also been trialled in animal models and were found to reduce choroidal neovascularisation [37]. Interestingly, the TZDs in this study were given by intraocular injection, suggesting that this delivery route of PPAR agonists might also be efficacious in humans [37]. Against the use of TZDs in the treatment of DR are the findings that systemic administration of troglitazone in humans was associated with increased vascular endothelial growth factor (VEGF) expression [38] and with an increased risk of diabetic macular oedema (DMO) [39].…”

Section: Introductionmentioning

confidence: 99%

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

Treacy

Hurst

2012

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundSystemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.DiscussionBased on the evidence of large-scale clinical studies investigating the systemic administration of fenofibrate, this ligand for peroxisome proliferator-activated receptor-α is potentially a good candidate for intraocular delivery. Here, we describe the mechanisms by which it might be acting to improve diabetic retinopathy, its relative safety and we speculate on how it could be developed for intraocular delivery.SummaryIn this paper, we provide a rationale for the further investigation of peroxisome proliferator-activated receptor-α agonists as intraocular agents for the treatment of diabetic retinopathy.

show abstract

Seroreactivity Against Aqueous-Soluble and Detergent-Soluble Retinal Proteins in Posterior Uveitis

Brinton²,

Mahajan³

et al. 2011

Arch Ophthalmol

View full text Add to dashboard Cite

To characterize the seroreactivity against retinal proteins in patients with posterior uveitis, retinal disease of noninflammatory origin, and healthy controls. Methods: Patients with posterior uveitis (n =47), molecularly confirmed photoreceptor degenerations (n=11), and healthy controls (n=33) received dilated fundus examinations at the University of Iowa. Aqueous-soluble and detergent-soluble fractions of human retina were separated by gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were probed with patient serum samples to detect IgG, IgA, and IgM human antibodies that react with retinal antigens. The number of bands detected by Western blot was counted, and their molecular weights were determined. Results: Antibodies recognizing retinal proteins were found in healthy controls, in patients with posterior uveitis, and in patients with molecularly confirmed heri

show abstract

Controversies of Diagnosing Autoimmune Retinopathy

Cited by 7 publications

References 0 publications

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

Seroreactivity Against Aqueous-Soluble and Detergent-Soluble Retinal Proteins in Posterior Uveitis

Contact Info

Product

Resources

About